India orders safety review of glucagon-like peptide-1 weight-loss drugs
Change
India ordered the Indian Pharmacopoeia Commission to compile monthly or bi-monthly adverse-event reports on glucagon-like peptide-1 (GLP-1) receptor agonist weight-loss drugs and directed state and union territory drug controllers to step up enforcement against surrogate advertising and improper marketing.
Why it matters
Marketing authorisation holders and drug manufacturers must now operate under a recurring post-market surveillance schedule that requires regular adverse-event reporting to a central agency, increasing mandatory compliance and documentation duties. Regional drug controllers are required to pursue enforcement for significant promotional violations, making non-compliant advertising and off-label promotion subject to regulatory action.
Implications
- — Marketing authorisation holders' regulatory teams must submit adverse-event and risk-management data to the Indian Pharmacopoeia Commission on the monthly or bi-monthly schedule or face enforcement action by state or union territory drug controllers.
- — Pharmacovigilance officers at drug manufacturers and importers must escalate and document safety signals to the Indian Pharmacopoeia Commission according to the new review cadence or risk regulatory scrutiny and enforcement.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer